DGAP-News: aap Implantate AG
/ Key word(s): Quarter Results/Preliminary Results
26.04.2021 / 14:35
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (“aap” or the “Company”) has started the financial year 2021 with good sales growth. Although the first quarter was still strongly impacted by the still rampant COVID 19 pandemic, aap increased sales by 9% year-on-year to EUR 2.7 million (Q1/2020: EUR 2.5 million) according to preliminary figures. Taking into account constant exchange rates, the growth rate was even 12%. It should be noted that the COVID 19 pandemic last year was not reflected in the business development until mid-March, so that the realized sales growth is to be assessed all the higher against the backdrop of the continuing comprehensive lockdown measures, which were recently even tightened in some cases. Not least, at the end of March aap received customer orders from tenders with a total value of around EUR 0.5 million, which have now been postponed to the second quarter due to their late receipt. If the orders had been received on time, sales in the first quarter would have been visibly above EUR 3 million.
Looking at the individual regions, aap was able to report a recovery in business both in Germany (+15%) and international (excluding the USA; +14%) despite the still noticeable effects of the COVID 19 pandemic and achieved corresponding sales increases. However, the picture at international level is ambivalent: While performance in Europe continues to be impacted by the comprehensive lockdown measures and a vaccination campaign that is only progressing slowly, as reflected in a 13% decline, sales in the BRICS region almost doubled (+91%), mainly due to increased demand in Brazil. In the rest of the world (RoW), however, sales in the first quarter were virtually unchanged from the corresponding prior-year level.
In the USA, aap continues to record dynamic development: In the first three months, more than 500 surgeries were performed with aap products, more than ever before. Based on this, sales in the US distribution business increased by 24% to EUR 0.7 million. In the overall US market, sales development in the first quarter of 2021 stabilized at the level of the previous year, as the first quarter of 2020 was still impacted by a major order from a global partner, which thereafter only ordered consumables on a much smaller scale. Basically, the trend shown – continuous increase in weekly surgeries – supports the achievement of the ambitious growth targets for 2021 in the USA. This momentum is driven particularly by the contracts concluded with US-wide purchasing associations and networks (currently: ten contracts concluded) that give aap access to an extensive network of clinics and surgical operation centers.
For the second quarter of 2021, aap expects sales growth as well and plans a sales level above the EUR 3 million mark (Q2/2020: EUR 1.9 million, H1/2020: EUR 4.4 million). This outlook is supported by an order book that is currently already filled with around EUR 0.6 million. However, this only applies under the condition that the COVID 19 pandemic continues to ease and no additional drastic lockdown measures are imposed.
The figures contained in this press release are preliminary as of 31 March 2021, which may still change until final publication. aap plans to announce the final results for the first quarter of 2021 in a press release in May.
About aap Implantate AG
For queries, please contact:
aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 – 134; Fax: +49 (0)30 75019 – 290; Email: email@example.com
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1188235|
|End of News||DGAP News Service|